Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Phathom Pharmaceuticals (PHAT) Cash & Current Investments: 2022-2025

Historic Cash & Current Investments for Phathom Pharmaceuticals (PHAT) over the last 4 years, with Sep 2025 value amounting to $138.0 million.

  • Phathom Pharmaceuticals' Cash & Current Investments fell 59.11% to $138.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $805.8 million, marking a year-over-year decrease of 39.23%. This contributed to the annual value of $300.1 million for FY2024, which is 21.89% down from last year.
  • Per Phathom Pharmaceuticals' latest filing, its Cash & Current Investments stood at $138.0 million for Q3 2025, which was down 9.46% from $152.4 million recorded in Q2 2025.
  • Over the past 5 years, Phathom Pharmaceuticals' Cash & Current Investments peaked at $384.3 million during Q4 2023, and registered a low of $130.1 million during Q1 2023.
  • Its 3-year average for Cash & Current Investments is $248.0 million, with a median of $249.4 million in 2023.
  • As far as peak fluctuations go, Phathom Pharmaceuticals' Cash & Current Investments spiked by 149.92% in 2024, and later tumbled by 59.11% in 2025.
  • Over the past 4 years, Phathom Pharmaceuticals' Cash & Current Investments (Quarterly) stood at $155.9 million in 2022, then spiked by 146.49% to $384.3 million in 2023, then dropped by 21.89% to $300.1 million in 2024, then plummeted by 59.11% to $138.0 million in 2025.
  • Its last three reported values are $138.0 million in Q3 2025, $152.4 million for Q2 2025, and $215.2 million during Q1 2025.